<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Med Res</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Med Res</journal-id><journal-title-group><journal-title>European Journal of Medical Research</journal-title></journal-title-group><issn pub-type="ppub">0949-2321</issn><issn pub-type="epub">2047-783X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">11225336</article-id><article-id pub-id-type="publisher-id">1897</article-id><article-id pub-id-type="doi">10.1186/s40001-024-01897-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>M2-type tumor-associated macrophages upregulated PD-L1 expression in cervical cancer via the PI3K/AKT pathway</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Guo</surname><given-names>Fan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Kong</surname><given-names>Weina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Dewei</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Gang</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Anwar</surname><given-names>Miyessar</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Feifei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yuanming</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ma</surname><given-names>Cailing</given-names></name><address><email>hymcl13009661999@126.com</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ma</surname><given-names>Xiumin</given-names></name><address><email>mxm20190216@sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01p455v08</institution-id><institution-id institution-id-type="GRID">grid.13394.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1799 3993</institution-id><institution>Department of Medical Laboratory Center, </institution><institution>Tumor Hospital Affiliated to Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, </institution></institution-wrap>No 789 Suzhou Road, Urumqi, 830011 Xinjiang China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01p455v08</institution-id><institution-id institution-id-type="GRID">grid.13394.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1799 3993</institution-id><institution>Postdoctoral Research Workstation of Tumor Hospital Affiliated to Xinjiang Medical University, </institution></institution-wrap>Urumqi, Xinjiang China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02r247g67</institution-id><institution-id institution-id-type="GRID">grid.410644.3</institution-id><institution>Center of Respiratory and Critical Care Medicine, </institution><institution>The People&#x02019;s Hospital of the Xinjiang Uygur Autonomous Region, </institution></institution-wrap>Urumqi, Xinjiang China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.13394.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1799 3993</institution-id><institution>Department of Blood Transfusion, </institution><institution>Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University, </institution></institution-wrap>Urumqi, Xinjiang China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01p455v08</institution-id><institution-id institution-id-type="GRID">grid.13394.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1799 3993</institution-id><institution>Tumor Hospital Affiliated to Xinjiang Medical University, </institution></institution-wrap>Urumqi, Xinjiang China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02qx1ae98</institution-id><institution-id institution-id-type="GRID">grid.412631.3</institution-id><institution>Department of Gynecology, </institution><institution>The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, </institution></institution-wrap>137 Li Yu Shan South Road, Urumqi, 830054 Xinjiang China </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>29</volume><elocation-id>357</elocation-id><history><date date-type="received"><day>23</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>5</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background and purpose</title><p id="Par1">PD-1/PD-L1 inhibitors have become a promising therapy. However, the response rate is lower than 30% in patients with cervical cancer (CC), which is related to immunosuppressive components in tumor microenvironment (TME). Tumor-associated macrophages (TAMs), as one of the most important immune cells, are involved in the formation of tumor suppressive microenvironment. Therefore, it will provide a theoretical basis for curative effect improvement about the regulatory mechanism of TAMs on PD-L1 expression.</p></sec><sec><title>Methods</title><p id="Par2">The clinical data and pathological tissues of CC patients were collected, and the expressions of PD-L1, CD68 and CD163 were detected by immunohistochemistry. Bioinformatics was used to analyze the macrophage subtypes involved in PD-L1 regulation. A co-culture model was established to observe the effects of TAMs on the morphology, migration and invasion function of CC cells, and the regulatory mechanism of TAMs on PD-L1.</p></sec><sec><title>Results</title><p id="Par3">PD-L1 expression on tumor cells could predict the poor prognosis of patients. And there was a strong correlation between PD-L1 expression with CD163<sup>+</sup>TAMs infiltration. Similarly, PD-L1 expression was associated with M1/M2-type TAMs infiltration in bioinformatics analysis. The results of cell co-culture showed that M1/M2-type TAMs could upregulate PD-L1 expression, especially M2-type TAMs may elevate the PD-L1 expression via PI3K/AKT pathway. Meanwhile, M1/M2-type TAMs can affect the morphological changes, and enhance migration and invasion abilities of CC cells.</p></sec><sec><title>Conclusions</title><p id="Par4">PD-L1 expression in tumor cells can be used as a prognostic factor and is closely related to CD163<sup>+</sup>TAMs infiltration. In addition, M2-type TAMs can upregulate PD-L1 expression in CC cells through PI3K/AKT pathway, enhance the migration and invasion capabilities, and affect the tumor progression.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cervical cancer</kwd><kwd>Tumor-associated macrophages (TAMs)</kwd><kwd>Prognosis</kwd><kwd>Tumor microenvironment (TME)</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009110</institution-id><institution>Natural Science Foundation of Xinjiang Uygur Autonomous Region</institution></institution-wrap></funding-source><award-id>2021D01C402</award-id><principal-award-recipient><name><surname>Guo</surname><given-names>Fan</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Talent Support Project of the Tumor Hospital Affiliated to Xinjiang Medical University</institution></funding-source><award-id>2021KX002</award-id><principal-award-recipient><name><surname>Guo</surname><given-names>Fan</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>the special scientific research project of young medical scientific and technological talents of Xinjiang Uygur Autonomous region Health and Family Planning Commission</institution></funding-source><award-id>WJWY-202403</award-id><principal-award-recipient><name><surname>Guo</surname><given-names>Fan</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>the "Tianchi Excellence" Program of Xinjiang Uygur Autonomous region</institution></funding-source><award-id>2022TCYCGF</award-id><principal-award-recipient><name><surname>Guo</surname><given-names>Fan</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>the Postdoctoral Fund of Tumor Hospital Affiliated to Xinjiang Medical University</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>the Excellent Postdoctoral Program of Xinjiang Uygur Autonomous Region</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par23">Cervical cancer (CC), as a malignant tumor, is one of the leading causes of death in women, accounting for approximately 12% of female cancers [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Despite improvements in the early diagnosis and treatment of CC, data from the World Health Organization showed that there were still 604,127 new cases and 341,831 deaths in 2020 [<xref ref-type="bibr" rid="CR3">3</xref>]. It is well known that patients with early stage can be cured by surgery, and simultaneous radiotherapy and chemotherapy are the preferred treatment for patients with locally advanced CC. However, there is a high probability for recurrence and metastasis in patients with advanced CC, resulting in a median overall survival (OS) of only 16.8&#x000a0;months [<xref ref-type="bibr" rid="CR4">4</xref>], which indicates that the therapeutic efficacy is limited. In China, the onset age of CC is getting younger, and Xinjiang is a region with a high incidence of CC [<xref ref-type="bibr" rid="CR5">5</xref>]. Therefore, it is an urgent clinical problem to improve the therapeutic effect of CC patients.</p><p id="Par24">Recently, an increasing number of studies have revealed the remarkable therapeutic effects of immunotherapy [<xref ref-type="bibr" rid="CR6">6</xref>]. The programmed cell death factor 1 (PD-1) / programmed cell death ligand 1 (PD-L1) inhibitor, as classical immune checkpoint inhibitors (ICIs), have achieved good clinical outcomes in various solid tumors and are considered to be a promising tumor treatment strategy. Pembrolizumab (MK-3475), a PD-1 inhibitor, was initially studied in KEYNOTE-028. The 24 patients with PD-L1-positive advanced CC were enrolled, and the objective response rate (ORR) reached 17% [<xref ref-type="bibr" rid="CR7">7</xref>]. KEYNOTE-158 is a further study of pembrolizumab. This cohort included 98 patients with recurrent or metastatic CC with an ORR of 12.2%, among which the ORR of PD-L1-positive CC patients reached 14.6% [<xref ref-type="bibr" rid="CR8">8</xref>]. Therefore, based on the safety and antitumor effects of pembrolizumab in KEYNOTE-158 clinical trials, pembrolizumab has been officially approved by the US Food and Drug Administration for patients with advanced PD-L1-positive CC who experienced progression during or after chemotherapy. Although pembrolizumab improved the curative effect of patients with CC, the patient response rate was lower than 30% [<xref ref-type="bibr" rid="CR9">9</xref>], considering to be associated with the immunosuppressive component in the tumor microenvironment (TME). Tumor-associated macrophages (TAMs), as one of the most important immune cells, are involved in the formation of tumor suppressive microenvironment. Hence, it will provide a new idea for curative effect improvement and combination therapy about the regulatory mechanism of TAMs on PD-L1 expression in CC.</p><p id="Par25">TAMs, which refer to macrophages infiltrated in tumor tissues or distributed in the TME, are the most abundant in number of immune cell population that play a key role in the TME [<xref ref-type="bibr" rid="CR10">10</xref>]. Currently, TAMs generally are divided into two main groups called classically activated macrophages (M1-type) and alternatively activated macrophages (M2-type) [<xref ref-type="bibr" rid="CR11">11</xref>]. The two polarization states of TAMs are dynamically changing under the stimulation of different signals during the process of tumor occurrence and development. It is found that M1-type TAMs are mainly dominant groups in the initial stage of malignant tumor to improve the immune effect and exert antitumor effects. However, the expression of molecules such as interleukin-4 (IL-4), colony-stimulating factor 1 (CSF-1) and arginnse-1 (Arg-1) in the TME are increased with the development of tumor, which induce the transformation of M1-type TAMs into M2-type TAMs. So M2-type TAMs gradually occupy an epigenetic advantage, promoting tumor development and drug resistance [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par26">Previous studies have shown that the infiltration of TAMs in TME can elevate PD-L1 expression levels on a variety of tumor cells, promote the formation of tumor immunosuppressive microenvironment, and thus mediate the immune escape of tumor cells [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. Therefore, TAMs are one of the regulatory factors for PD-L1 expression on tumor cells. In the mechanism study of Komura and Zhang et al., it was found that TAMs can upregulate the expression of PD-L1 in cancer cells by activating the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling pathway [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In CC, the expression of PD-L1 on tumor cells is highly correlated with the density of TAMs [<xref ref-type="bibr" rid="CR19">19</xref>]. There is currently insufficient evidence to indicate whether the correlation between PD-L1 and TAMs is caused by TAMs regulating PD-L1. Moreover, the PI3K/AKT pathway regulates multiple cellular and molecular functions, which are crucial for tumor initiation, invasion and metastasis. Previous studies have shown that the PI3K/AKT pathway is often dysregulated in CC [<xref ref-type="bibr" rid="CR20">20</xref>]. Therefore, the mechanism of TAMs activating PD-L1 expression on CC cells needs to be further explored.</p><p id="Par27">Taken together, TAMs, as one of the important immune cells in TME, play a crucial role in the occurrence and development of tumors. TAMs can inhibit the recruitment and activation of T cells, regulate PD-L1 expression on tumor cells, and usually form a tumor suppressive microenvironment to affect the therapeutic efficacy of PD-1/PD-L1 inhibitors. There are two parts in our research. One part related to the study of clinical CC patient specimens and their survival rate. We performed immunohistochemistry (IHC) staining on CC patient tissues to observe the expression of TAMs and PD-L1, and analyzed the relationship between them. Moreover, the effect of PD-L1 on survival time of patients with CC was analyzed. And the other part related to the in vitro investigation of TAMs co-culturing with CC cell lines, aiming to explore the influence of TAMs on the biological behavior of CC cells and the regulatory mechanism of PD-L1. Meanwhile, bioinformatics was used to analyze the macrophage subtypes involved in PD-L1 regulation in the TCGA-CESC database. This is of great significance for screening the advantageous population of immunotherapy and guiding the clinical application of PD-1/PD-L1 inhibitors.</p></sec><sec id="Sec2"><title>Material and methods</title><sec id="Sec3"><title>Collection of clinical data and patients samples</title><p id="Par28">The clinical data and pathological embedded tissues of 98 patients with CC were collected from the Tumor Hospital Affiliated to Xinjiang Medical University after ethical review. Inclusion criteria: patients with CC diagnosed by pathological gold standard and had complete clinical data and paraffin pathological specimens. Exclusion criteria: history of other malignant tumors, autoimmune diseases, and during pregnancy or lactation. The survival status of 98 patients with CC in the study was followed up, mainly through medical record system inquiry and telephone follow-up. The &#x000a0;patients'&#x000a0;OS was set as the time interval from the initial diagnosis of CC to the final death due to tumor factors or the last follow-up.</p></sec><sec id="Sec4"><title>IHC staining</title><p id="Par29">IHC staining was used to analyze the expression of PD-L1, CD68 and CD163 in CC tissues. The procedures of IHC staining was as follows: baking tissue sections, dewaxing in xylene, hydrating in gradient alcohol, repairing antigen in microwave oven, inactivating endogenous peroxidase, blocking in goat serum, incubating antibodies, coloring, differentiating of hydrochloric acid ethanol and dehydrating, etc. The primary antibodies included rabbit anti-PD-L1 (ab213524, Abcam), mouse anti-CD68 (ab955, Abcam), and mouse anti-CD163 (TA506381, OriGene Technologies, Inc.). Evaluation of positive staining was performed by two independent pathologists who were blinded to the clinical data of patients.</p></sec><sec id="Sec5"><title>Bioinformatics analysis</title><p id="Par30">The count matrix of transcriptome sequencing in TCGA-CESC database was downloaded by TCGAbiolinks package of R language. Gene set variation analysis (GSVA) package was used to analyze PD-L1 expression and the correlation of different subtypes of macrophages in TCGA-CESC database. Macrophages were divided into the following three types, and the gene signatures were as follows [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]:</p><p id="Par31">Macrophages: ANOS1, APOE, ATG7, BCAT1, CCL7, CD163, CD68, CD84, CHI3L1. CHIT1, CLEC5A, CTSK, CYBB, FN1, GM2A, GPC4, MARCO, MS4A4A, MSR1, RAI14, SCARB2, SGMS1.</p><p id="Par32">M1-type macrophages: CCL18, CCL2, CCL3, CCL4, CCL5, CCR7, CD40, CD80, CD86, CSF2, CXCL10, CXCL11, CXCL16, CXCL8, CXCL9, FCGR1A, FCGR1B, FCGR2A, FCGR2B, FCGR3A, FCGR3B, IDO1, IFNG, IL12A, IL12B, IL15, IL18, IL1A, IL1B, IL1R1, IL23A, IL6, IRF5, KYNU, MMP9, PTX3, STAT1, TLR2, TLR4, TNF.</p><p id="Par33">M2-type macrophages: ALOX15, ALOX5AP, ARG1, CCL1, CCL13, CCL17, CCL18, CCL22, CCL24, CCL4, CCR2, CCR3, CD14, CD163, CD200R1, CSF1, CXCL14, CXCR1, CXCR2, F13A1, FCER2, GATA3, HIF1a, ID3, IL10, IL13, IL17RB, IL1R1, IL4, IRF4, MARCO, MMP1, MMP12, MMP2, MRC1, MRC2, MSR1, NOS2, NR3C2, RGS1, SMAD2, SOCS1, SOCS3, SPP1, STAB1, STAT3, TGFB1, TGFBR2, TGM2.</p></sec><sec id="Sec6"><title>Cell culture</title><p id="Par34">The human CC cell lines (SiHa and HeLa) and the human monocytic leukemia cell line (THP-1) were obtained from Procell Life Science&#x00026;Technology Co., Ltd. Both SiHa and HeLa cell lines were adherent cells and were cultured in DMEM complete medium. THP-1 cell line was suspended cells and was cultured in 1640 complete medium. All cell lines were cultured in a cell incubator at 37 &#x000b0;C with 5% CO<sub>2</sub>. The induced differentiation of THP-1 cells was performed as follows: 1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> THP-1 cells were induced to adhere for 12&#x000a0;h with 320&#x000a0;nM PMA, then 100&#x000a0;ng/mL LPS and 20&#x000a0;ng/mL interferon-r (IFN-&#x003b3;) were added for 48&#x000a0;h to obtain M1-type TAMs, and 20&#x000a0;ng/mL IL-4 and 20&#x000a0;ng/mL lL-13 were added for 48&#x000a0;h to obtain M2-type TAMs.</p></sec><sec id="Sec7"><title>Establishment of cell co-culture system</title><p id="Par35">A non-contact co-culture system between CC cells and macrophages was established through Transwell cell chambers (0.4&#x000a0;&#x003bc;M) in vitro. The chamber was referred to as the upper chamber, which was inoculated THP-1 cell together with polarization cytokines to induce differentiating into M1/M2-type macrophage. The culture plate was called the lower chamber and inoculated with CC cells. The upper chambers contained induced macrophages were placed in the lower chambers seeded with CC cells, and co-cultured for 48&#x000a0;h. The 1640 complete medium was used for co-culture. It is worth noting that CC cells (SiHa and HeLa) were cultured using the 1640 complete medium for prior adaptation and stably passaged 3&#x02013;5 generations for co-culture.</p></sec><sec id="Sec8"><title>Cell invasion and migration</title><p id="Par36">Transwell 24-well cell culture plate (8&#x000a0;&#x003bc;M) was used in cell invasion. The Matrigel matrix glue was removed from &#x02013; 80&#x000a0;&#x000b0;C and restored to liquid at 4 &#x000b0;C, then mixed with serum-free 1640 medium into the Transwell upper chamber until fully solidified. The serum-free suspension of 1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> CC cells was added to the upper chamber and the medium with 20% high concentration of fetal bovine serum was added to the lower chamber to attract cells. And they were placed in a 5%CO<sub>2</sub> incubator at 37 &#x000b0;C. After 24&#x000a0;h, the upper chamber liquid was discarded, fixed with 4% paraformaldehyde for 20&#x000a0;min, and stained with 0.1% crystal violet solution for 20&#x000a0;min. The images could be taken for analysis after drying. Cell migration was performed without plating Matrigel matrix glue, and the remaining steps were the same as cell invasion.</p></sec><sec id="Sec9"><title>Flow cytometry</title><p id="Par37">The cells were harvested and suspended in a PBS buffer containing 0.2% BSA. Centrifuge at 1500 r/min for 5&#x000a0;min, discard the supernatant and repeat 3 times. The cells were then stained with anti-PD-L1 PE (329,706, Biolegend, USA) for 30&#x000a0;min at 4 &#x000b0;C in the dark. The cells were detected by flow cytometry.</p></sec><sec id="Sec10"><title>Quantitative real-time PCR (qRT-PCR)</title><p id="Par38">Total RNA was isolated from cells using Trizol according to the manufacturer&#x02019;s instructions. The extracted RNA was converted into cDNA with 5&#x02009;&#x000d7;&#x02009;gDNA eraser buffer, gDNA eraser, 5&#x02009;&#x000d7;&#x02009;primescript buffer 2, primescript RT enzyme mix I, RT primer mix and RNase free dH<sub>2</sub>O. The qRT-PCR was performed in the QuantStudio 6 Real Time PCR Detection System machine in the presence of GAPDH, tumor necrosis factor &#x003b1; (TNF-&#x003b1;), IL-1&#x003b2;, transforming growing factor &#x003b2; (TGF-&#x003b2;), CD163, and PD-L1. The transcription level of target genes was measured and normalized to GAPDH expression. The following primer sequences were used: GAPDH, 5&#x02032;-GGCAAATTCCATGGCACCGT-3&#x02032; (forward) and 5&#x02032;-TGGACTCCACGACGTACTCA-3&#x02032; (reverse); TNF-&#x003b1;, 5&#x02032;-TGCACTTTGGAGTGATCGGC-3&#x02032; (forward) and 5&#x02032;-ACTCGGGGTTCGAGAAGATG-3&#x02032; (reverse); IL-1&#x003b2;, 5&#x02032;-CAGTGGCAATGAGGATGA-3&#x02032; (forward) and 5&#x02032;-TGTAGTGGTGGTCGGAGA-3&#x02032; (reverse); TGF-&#x003b2;, 5&#x02032;-CGTGCTAATGGTGGAAACCC-3&#x02032; (forward) and 5&#x02032;-TTCAGGTACCGCTTCTCGGA-3&#x02032; (reverse); CD163, 5&#x02032;-GCGGGAGAGTGGAAGTGAAAG-3&#x02032; (forward) and 5&#x02032;-GTTACAAATCACAGAGACCGCT-3&#x02032; (reverse); PD-L1, 5&#x02032;-TATGGTGGTGCCGACTACAA-3&#x02032; (forward) and 5&#x02032;-TGCTTGTCCAGATGACTTCG-3&#x02032; (reverse).</p></sec><sec id="Sec11"><title>Statistical analysis</title><p id="Par39">GraphPad Prism 8.0 software was used for data statistical analysis. One-way analysis of variance was used to compare the mean values among groups of data with normal distribution. A nonparametric test was used to compare the mean values among groups of data with non-normal distribution. Counting data were descripted by percentage (%). And comparative analysis was performed using Pearson Chi-square test or Fisher exact test. Linear correlation or Spearman correlation analysis was used for correlation between two variables. Kaplan&#x02013;Meier method was used to draw the patients' overall survival curve, and log-rank test was used to evaluate the difference of survival time between the two groups. A two-tailed test was used for all analyses. <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec12"><title>Results</title><sec id="Sec13"><title>PD&#x02011;L1 expression and the infiltration of CD68<sup>+</sup> and CD163<sup>+</sup> macrophages</title><p id="Par40">Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows the IHC staining images of PD-L1, CD68, and CD163. And IHC staining of PD-L1, CD68 and CD163 were performed in 98 patient tissues. The positive expression staining is brown. It was observed that PD-L1 was mainly expressed in the cytoplasm and membrane of tumor cells, and also partially expressed in stromal cells (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A). Among 98 patients with CC (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), 51 patients (52.04%) showed positive expression of PD-L1 on tumor cells, which was related to the patient's fertility history (<italic>p</italic>&#x02009;=&#x02009;0.0042), abortion history (<italic>p</italic>&#x02009;=&#x02009;0.0167), differentiation grade (<italic>p</italic>&#x02009;=&#x02009;0.0381) and FIGO stage (<italic>p</italic>&#x02009;=&#x02009;0.0440). PD-L1 was positively expressed in stromal cells in 45 patients (45.92%), which was related to fertility history (<italic>p</italic>&#x02009;=&#x02009;0.0014), abortion history (<italic>p</italic>&#x02009;=&#x02009;0.0100), tumor size (<italic>p</italic>&#x02009;=&#x02009;0.0167) and FIGO stage (<italic>p</italic>&#x02009;=&#x02009;0.0000). Moreover, the positive expression of CD68<sup>+</sup> and CD163<sup>+</sup> macrophages was mainly in the cell membrane, and the median distribution of intratumoral density in 98 CC samples was 14.0 and 12.0, respectively (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B, C). Meanwhile, the infiltration of CD68<sup>+</sup> and CD163<sup>+</sup> macrophages in CC tissue was positively correlated with the expression of PD-L1 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). There was a weak correlation between the PD-L1 expression on tumor cells and the infiltration of CD68<sup>+</sup> macrophages (<italic>r</italic>&#x02009;=&#x02009;0.2957, <italic>p</italic>&#x02009;=&#x02009;0.0031, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A), and a strong correlation between PD-L1 expression on interstitial cells and the infiltration of CD68<sup>+</sup> macrophages (<italic>r</italic>&#x02009;=&#x02009;0.8369, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B). PD-L1 expression on tumor cells was strongly correlated with the infiltration of CD163<sup>+</sup> macrophages (<italic>r</italic>&#x02009;=&#x02009;0.8582, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C), and PD-L1 expression on interstitial cells was moderately related to the infiltration of CD163<sup>+</sup> macrophages (<italic>r</italic>&#x02009;=&#x02009;0.4232, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>D). These results indicated that the correlation between CD163 density and PD-L1 expression in tumor cells was stronger than that of CD68 density. And the correlation between CD163<sup>+</sup> macrophages infiltration and PD-L1 expression in tumor cells was higher than that of stromal cells.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Immunohistochemistry staining for PD-L1, CD68<sup>+</sup> and CD163<sup>+</sup> macrophages in patients with cervical cancer. <bold>A</bold> PD-L1 expression. <bold>B</bold> CD68<sup>+</sup> macrophages expression. <bold>C</bold> CD163<sup>+</sup> macrophages expression. The left panel shows positive staining for PD-L1 and high macrophage density. The right panel shows negative staining for PD-L1 and low macrophage density</p></caption><graphic xlink:href="40001_2024_1897_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Analysis of PD-L1 expression and clinical characteristics in patients with cervical cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Clinical characteristics</th><th align="left" rowspan="2">Cases (%)</th><th align="left" colspan="2">PD-L1 expression on tumor cells</th><th align="left" rowspan="2"><italic>P</italic></th><th align="left" colspan="2">PD-L1 expression on mesenchymal cells</th><th align="left" rowspan="2"><italic>P</italic></th></tr><tr><th align="left">Negative (%)</th><th align="left">Positive (%)</th><th align="left">Negative (%)</th><th align="left">Positive (%)</th></tr></thead><tbody><tr><td align="left">All cases</td><td align="left">98</td><td align="left">47 (47.96)</td><td align="left">51 (52.04)</td><td char="." align="char"/><td align="left">53 (54.08)</td><td align="left">45 (45.92)</td><td char="." align="char"/></tr><tr><td align="left"><italic>Age</italic></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.5329</td><td align="left"/><td align="left"/><td char="." align="char">0.5649</td></tr><tr><td align="left">&#x02009;&#x0003c;&#x02009;50</td><td align="left">51 (52.04)</td><td align="left">26 (50.98)</td><td align="left">25 (49.02)</td><td char="." align="char"/><td align="left">29 (56.86)</td><td align="left">22 (43.14)</td><td char="." align="char"/></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;50</td><td align="left">47 (47.96)</td><td align="left">21 (44.68)</td><td align="left">26 (55.32)</td><td char="." align="char"/><td align="left">24 (51.06)</td><td align="left">23 (48.94)</td><td char="." align="char"/></tr><tr><td align="left"><italic>Ethnicity</italic></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.7560</td><td align="left"/><td align="left"/><td char="." align="char">0.0936</td></tr><tr><td align="left">Han</td><td align="left">37 (37.76)</td><td align="left">17 (45.95)</td><td align="left">20 (54.05)</td><td char="." align="char"/><td align="left">16 (43.24)</td><td align="left">21 (56.76)</td><td char="." align="char"/></tr><tr><td align="left">Other minorities</td><td align="left">61 (62.24)</td><td align="left">30 (49.18)</td><td align="left">31 (50.82)</td><td char="." align="char"/><td align="left">37 (60.66)</td><td align="left">24 (39.34)</td><td char="." align="char"/></tr><tr><td align="left"><italic>HPV</italic></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.3097</td><td align="left"/><td align="left"/><td char="." align="char">0.3747</td></tr><tr><td align="left">HPV 16</td><td align="left">36 (36.73)</td><td align="left">16 (44.44)</td><td align="left">20 (55.56)</td><td char="." align="char"/><td align="left">20 (55.56)</td><td align="left">16 (44.44)</td><td char="." align="char"/></tr><tr><td align="left">HPV 18</td><td align="left">29 (29.59)</td><td align="left">11 (37.93)</td><td align="left">18 (62.07)</td><td char="." align="char"/><td align="left">14 (48.28)</td><td align="left">15 (51.72)</td><td char="." align="char"/></tr><tr><td align="left">Other</td><td align="left">20 (20.41)</td><td align="left">11 (55.00)</td><td align="left">9 (45.00)</td><td char="." align="char"/><td align="left">12 (60.00)</td><td align="left">8 (40.00)</td><td char="." align="char"/></tr><tr><td align="left">Negative</td><td align="left">13 (13.27)</td><td align="left">3 (23.08)</td><td align="left">10 (76.92)</td><td char="." align="char"/><td align="left">10 (76.92)</td><td align="left">3 (23.08)</td><td char="." align="char"/></tr><tr><td align="left"><italic>Fertility history</italic></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.0042</td><td align="left"/><td align="left"/><td char="." align="char">0.0014</td></tr><tr><td align="left">0&#x02013;2 times</td><td align="left">52 (53.06)</td><td align="left">32 (61.54)</td><td align="left">20 (38.46)</td><td char="." align="char"/><td align="left">36 (69.23)</td><td align="left">16 (30.77)</td><td char="." align="char"/></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;3 times</td><td align="left">46 (46.94)</td><td align="left">15 (32.61)</td><td align="left">31 (67.39)</td><td char="." align="char"/><td align="left">17 (36.96)</td><td align="left">29 (63.04)</td><td char="." align="char"/></tr><tr><td align="left"><italic>Abortion history</italic></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.0167</td><td align="left"/><td align="left"/><td char="." align="char">0.0100</td></tr><tr><td align="left">Yes</td><td align="left">42 (42.86)</td><td align="left">26 (61.90)</td><td align="left">16 (38.10)</td><td char="." align="char"/><td align="left">29 (69.05)</td><td align="left">13 (30.95)</td><td char="." align="char"/></tr><tr><td align="left">No</td><td align="left">56 (57.14)</td><td align="left">21 (37.50)</td><td align="left">35 (62.50)</td><td char="." align="char"/><td align="left">24 (42.86)</td><td align="left">32 (57.14)</td><td char="." align="char"/></tr><tr><td align="left"><italic>Tumor size</italic></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.5837</td><td align="left"/><td align="left"/><td char="." align="char">0.0167</td></tr><tr><td align="left">&#x02009;&#x02264;&#x02009;4&#x000a0;cm</td><td align="left">41 (41.84)</td><td align="left">21 (51.22)</td><td align="left">20 (48.78)</td><td char="." align="char"/><td align="left">28 (68.29)</td><td align="left">13 (31.71)</td><td char="." align="char"/></tr><tr><td align="left">&#x02009;&#x0003e;&#x02009;4&#x000a0;cm</td><td align="left">57 (58.16)</td><td align="left">26 (45.61)</td><td align="left">31 (54.39)</td><td char="." align="char"/><td align="left">25 (43.86)</td><td align="left">32 (56.14)</td><td char="." align="char"/></tr><tr><td align="left"><italic>Differentiation</italic></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.0381</td><td align="left"/><td align="left"/><td char="." align="char">0.9337</td></tr><tr><td align="left">Low</td><td align="left">44 (44.90)</td><td align="left">16 (36.36)</td><td align="left">28 (63.64)</td><td char="." align="char"/><td align="left">24 (54.55)</td><td align="left">20 (45.45)</td><td char="." align="char"/></tr><tr><td align="left">Middle/high</td><td align="left">54 (55.10)</td><td align="left">31 (57.41)</td><td align="left">23 (42.59)</td><td char="." align="char"/><td align="left">29 (53.70)</td><td align="left">25 (46.30)</td><td char="." align="char"/></tr><tr><td align="left"><italic>Lymph node metastases</italic></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.1301</td><td align="left"/><td align="left"/><td char="." align="char">0.0972</td></tr><tr><td align="left">Yes</td><td align="left">77 (78.57)</td><td align="left">40 (51.95)</td><td align="left">37 (48.05)</td><td char="." align="char"/><td align="left">45 (58.44)</td><td align="left">32 (41.56)</td><td char="." align="char"/></tr><tr><td align="left">No</td><td align="left">21 (21.43)</td><td align="left">7 (33.33)</td><td align="left">14 (66.67)</td><td char="." align="char"/><td align="left">8 (38.10)</td><td align="left">13 (61.90)</td><td char="." align="char"/></tr><tr><td align="left"><italic>FIGO stage</italic></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.0440</td><td align="left"/><td align="left"/><td char="." align="char">0.0000</td></tr><tr><td align="left">IA-IB</td><td align="left">48 (48.98)</td><td align="left">28 (58.33)</td><td align="left">20 (41.67)</td><td char="." align="char"/><td align="left">38 (79.17)</td><td align="left">10 (20.83)</td><td char="." align="char"/></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;IIA</td><td align="left">50 (51.02)</td><td align="left">19 (38.00)</td><td align="left">31 (62.00)</td><td char="." align="char"/><td align="left">15 (30.00)</td><td align="left">35 (70.00)</td><td char="." align="char"/></tr></tbody></table></table-wrap><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Correlation of PD-L1 expression and infiltration of CD68<sup>+</sup> and CD163<sup>+</sup> macrophages in patients with cervical cancer. <bold>A</bold> PD-L1 in tumor cells and CD68<sup>+</sup> macrophages. <bold>B</bold> PD-L1 in stromal cells and CD68<sup>+</sup> macrophages. <bold>C</bold> PD-L1 in tumor cells and CD163<sup>+</sup> macrophages. <bold>D</bold> PD-L1 in stromal cells and CD163<sup>+</sup> macrophages</p></caption><graphic xlink:href="40001_2024_1897_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec14"><title>Effect of PD-L1 expression on prognosis of patients with CC</title><p id="Par41">19 cases of patients eventually died during the follow-up period of the 98 patients with CC. Since PD-L1 is mainly expressed on tumor cells and partly on stromal cells, we analyzed the influence of PD-L1 expression in different cells on patient prognosis. Log-rank test results showed that there was a statistically significant difference between the positive and negative expression of PD-L1 on tumor cells in CC tissue (<italic>p</italic>&#x02009;=&#x02009;0.0254, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A). However, there was no significant difference in OS between positive and negative expression of PD-L1 on stromal cells (<italic>p</italic>&#x02009;=&#x02009;0.8211, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B). In summary, the high expression of PD-L1 on tumor cells can predict poor prognosis of patients.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Kaplan&#x02013;Meier overall survival curves of PD-L1 expression on tumor and stromal cells in patients with cervical cancer. <bold>A</bold> Kaplan&#x02013;Meier overall survival curve of PD-L1 expression on tumor cells. <bold>B</bold> Kaplan&#x02013;Meier overall survival curve of PD-L1 expression on stromal cells</p></caption><graphic xlink:href="40001_2024_1897_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec15"><title>Correlation between the expression of PD-L1 and M1/M2-type TAMs-related molecules in TCGA-CESC database</title><p id="Par42">Through bioinformatics analysis of TCGA-CESC database, GSVA results showed that the expression of PD-L1 was positively related to pan-macrophages (<italic>r</italic>&#x02009;=&#x02009;0.4279, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), M1-type macrophages (<italic>r</italic>&#x02009;=&#x02009;0.5837, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) and M2-type macrophages (<italic>r</italic>&#x02009;=&#x02009;0.4858, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001).</p><p id="Par43">In addition, there is a positive correlation between PD-L1 expression and CD molecules associated with M1/M2-type TAMs including CD64A, CD80, CD86, CD163, CD200R and CD206. M1-type TAMs (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A): CD64A (<italic>r</italic>&#x02009;=&#x02009;0.4941, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), CD80 (<italic>r</italic>&#x02009;=&#x02009;0.6242, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) and CD86 (<italic>r</italic>&#x02009;=&#x02009;0.6047, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). M2-type TAMs (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B): CD163 (<italic>r</italic>&#x02009;=&#x02009;0.4374, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), CD200R (r&#x02009;=&#x02009;0.4130, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) and CD206 (<italic>r</italic>&#x02009;=&#x02009;0.2972, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). Moreover, PD-L1 expression was also positively correlated with cytokines related to M1/M2-type TAMs (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C, D), including the cytokines of M1-type TAMs such as IL-1&#x003b1; (<italic>r</italic>&#x02009;=&#x02009;0.2533, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), IL-1&#x003b2; (<italic>r</italic>&#x02009;=&#x02009;0.3634, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), and TNF-&#x003b1; (<italic>r</italic>&#x02009;=&#x02009;0.2886, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), as well as the cytokines such as CSF1 (<italic>r</italic>&#x02009;=&#x02009;0.4478, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), IL-10 (<italic>r</italic>&#x02009;=&#x02009;0.4305, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) and TGF-&#x003b2;1 (<italic>r</italic>&#x02009;=&#x02009;0.2740, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) of M2-type TAMs. Unfortunately, PD-L1 expression was weakly correlated with most TAMs-elated cytokines. All the above results indicated that PD-L1 expression in TCGA-CESC data may be associated with M1/M2-type macrophage-related CD molecules and cytokines.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Correlation analysis between PD-L1 expression and TAMs-related factors. <bold>A</bold> PD-L1 expression and M1-type TAMs-related CD molecules: CD64A, CD80 and CD86. <bold>B</bold> PD-L1 expression and M2-type TAMs-related CD molecules: CD163, CD200R and CD206. <bold>C</bold> PD-L1 expression and M1-type TAMs-related cytokines: IL-1&#x003b1;, IL-1&#x003b2; and TNF-&#x003b1;. <bold>D</bold> PD-L1 expression and M2-type TAMs-related cytokines: CSF1, IL-10 and TGF-&#x003b2;1</p></caption><graphic xlink:href="40001_2024_1897_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec16"><title>Identification of induced differentiation of macrophages cells</title><p id="Par44">THP-1 cells were induced by LPS&#x02009;+&#x02009;IFN-&#x003b3; and IL-4&#x02009;+&#x02009;IL-13 to obtain M1-type and M2-ype macrophages, respectively. It was found that THP-1 cells were round or ovoid in morphology and suspended in the culture medium for growth (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A, <xref rid="Fig5" ref-type="fig">B</xref>). M0-type macrophages were induced by the addition of PMA, becoming spindle-shaped in morphology. A few cells appeared pseudopodia, and the cell size became larger (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>C, <xref rid="Fig5" ref-type="fig">D</xref>). The morphology of cell was further changed after inducing with cytokines for 48&#x000a0;h. It was observed that the morphology of M1-type macrophages was mainly polygonal (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>E, <xref rid="Fig5" ref-type="fig">F</xref>). M2-type macrophages were mostly round and short spindle-shaped. And some cells had protruding pseudopodia and were prone to aggregation and growth (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>G, <xref rid="Fig5" ref-type="fig">H</xref>).<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Morphological changes in induced differentiation of THP-1 cells and detection of specific marker mRNA. <bold>A</bold>, <bold>B</bold> THP-1 cells. <bold>C</bold>, <bold>D</bold> M0-type macrophages. <bold>E</bold>, <bold>F</bold> M1-type macrophages. <bold>G</bold>&#x02013;<bold>H</bold> M2-type macrophages. <bold>I</bold> mRNA expression of TNF-&#x003b1;. <bold>J</bold> mRNA expression of IL-1&#x003b2;. <bold>K</bold> mRNA expression of TGF-&#x003b2;. <bold>L</bold> mRNA expression of CD163. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001</p></caption><graphic xlink:href="40001_2024_1897_Fig5_HTML" id="MO5"/></fig></p><p id="Par45">TNF-&#x003b1; and IL-1&#x003b2; were used as specific markers for M1-type macrophage, and TGF-&#x003b2; and CD163 were used as specific markers for M2-type macrophage. After differentiation induced by LPS and IFN-r, the expressions of TNF-&#x003b1; and IL-1&#x003b2; in M1-type macrophages were higher than those in M0-type macrophages (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>p</italic>&#x02009;=&#x02009;0.0435) and those in M2-type macrophages (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>p</italic>&#x02009;=&#x02009;0.0014), suggesting that M1-type macrophages was different from M0-type and M2-type macrophages (F<xref rid="Fig5" ref-type="fig">i</xref>g.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>I, <xref rid="Fig5" ref-type="fig">J</xref>). Similarly, after differentiation induced by IL-4 and IL-13, M2-type macrophages showed higher TGF-&#x003b2; and CD163 expression than M0-type macrophages (<italic>p</italic>&#x02009;=&#x02009;0.0174, <italic>p</italic>&#x02009;=&#x02009;0.0071) and M1-type macrophages (<italic>p</italic>&#x02009;=&#x02009;0.0254, <italic>p</italic>&#x02009;=&#x02009;0.0434), indicating that M2-type macrophages were different from M0-type and M1-type macrophages (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>K, <xref rid="Fig5" ref-type="fig">L</xref>). To sum up, based on the specific molecules detection and morphological changes, we successfully established the M1/M2-type macrophage model.</p></sec><sec id="Sec17"><title>Effects of co-culture on tumor cell morphology and function</title><p id="Par46">A co-culture system of CC cells and M1/M2-type macrophages was established through Transwell co-culture chamber. The results showed that the morphology of SiHa and HeLa cells changed greatly after co-culture with M1/M2-type macrophages. SiHa cells were blunt and round, with cobblestone-like arrangement and tight connections between cells (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A, <xref rid="Fig6" ref-type="fig">B</xref>). SiHa cells became a long spindle-shaped with disordered arrangement and wider intercellular space after co-culture, especially after co-culture with M2-type macrophages (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>E, <xref rid="Fig6" ref-type="fig">F</xref>, <xref rid="Fig6" ref-type="fig">I</xref>, <xref rid="Fig6" ref-type="fig">J</xref>). HeLa cells were polygonal with good intercellular integration (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>C, <xref rid="Fig6" ref-type="fig">D</xref>). After co-culture, the morphology of HeLa cells was irregularly round, and the degree of intercellular fusion was reduced, especially after co-culture with M2-type macrophages (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>G, <xref rid="Fig6" ref-type="fig">H</xref>, <xref rid="Fig6" ref-type="fig">K</xref>, <xref rid="Fig6" ref-type="fig">L</xref>).<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Morphological changes of cervical cancer cells after co-culturing with M1/M2-type macrophages. <bold>A</bold>, <bold>B</bold> Morphology of SiHa cell. <bold>C</bold>, <bold>D</bold> Morphology of HeLa cell. <bold>E</bold>, <bold>F</bold> The morphological change of SiHa cells after co-culturing with M1-type macrophages. <bold>G</bold>, <bold>H</bold> The morphological change of HeLa cells after co-culturing with M1-type macrophages. <bold>I</bold>, <bold>J</bold> The morphological change of SiHa cells after co-culturing with M2-type macrophages. <bold>K</bold>, <bold>L</bold> The morphological change of HeLa cells after co-culturing with M2-type macrophages</p></caption><graphic xlink:href="40001_2024_1897_Fig6_HTML" id="MO6"/></fig></p><p id="Par47">SiHa and HeLa cells were co-cultured with M1/M2-type macrophages for 24&#x000a0;h in Transwell chamber (8&#x000a0;&#x003bc;M). The migration and invasion ability of CC cells were observed by counting and quantitative analysis of cells that passed through the membrane of micropore. As shown in Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>, the number of SiHa cells passing through the chamber microporous membrane was significantly increased after co-culture, suggesting a significant enhancement in the migration and invasion ability of SiHa cells. M1-type macrophages enhanced the migration and invasion of SiHa cells (<italic>p</italic>&#x02009;=&#x02009;0.0012, <italic>p</italic>&#x02009;=&#x02009;0.0079). M2-type macrophages also play a similar role in SiHa cells (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>p</italic>&#x02009;=&#x02009;0.0011). In addition, compared with the control group, the migration and invasion ability of HeLa CC cells could be improved by M1-type macrophages (<italic>p</italic>&#x02009;=&#x02009;0.0396, <italic>p</italic>&#x02009;=&#x02009;0.0183) and M2-type macrophages (<italic>p</italic>&#x02009;=&#x02009;0.0121, <italic>p</italic>&#x02009;=&#x02009;0.0008) after co-culture. In conclusion, the above results indicated that the migration and invasion ability of CC cells was enhanced after co-culture with M1/M2-type macrophages, especially after co-culture with M2-type macrophages.<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>Effect of M1/M2-type macrophages on migration and invasion of cervical cancer cell. <bold>A</bold> Altered migration ability of SiHa cells after co-culturing with M1/M2-type macrophages. <bold>B</bold> Altered migration ability of HeLa cells after co-culturing with M1/M2-type macrophages. <bold>C</bold> Altered invasion ability of SiHa cells after co-culturing with M1/M2-type macrophages. <bold>D</bold> Altered invasion ability of HeLa cells after co-culturing with M1/M2-type macrophages. <bold>E</bold> Number of SiHa cell migration. <bold>F</bold> Number of HeLa cell migration. <bold>G</bold> Number of SiHa cell invasion. <bold>H</bold> Number of HeLa cell invasion. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001</p></caption><graphic xlink:href="40001_2024_1897_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec18"><title>M1/M2-type macrophages can promote the upregulation of PD-L1 expression in CC cells</title><p id="Par48">SiHa and HeLa cells were collected after co-culture with M1/M2-type macrophages for the detection of mRNA and protein levels of PD-L1. The results showed that the mRNA level of PD-L1 on SiHa cells increased by about 1.5 times after co-culture with M1/M2-type macrophages (<italic>p</italic>&#x02009;=&#x02009;0.0023, <italic>p</italic>&#x02009;=&#x02009;0.0002, Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>A). The mRNA expression level of PD-L1 on HeLa cells elevated about 4.0 times after co-culture with M1/M2-type macrophages (<italic>p</italic>&#x02009;=&#x02009;0.0041, <italic>p</italic>&#x02009;=&#x02009;0.0021, Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>D). Meanwhile, after co-culture with M2-type macrophages, the expression of PD-L1 protein on the surface of SiHa and HeLa cells was increased by approximately 1.4 times (<italic>p</italic>&#x02009;=&#x02009;0.0112, <italic>p</italic>&#x02009;=&#x02009;0.0231, Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>B, <xref rid="Fig8" ref-type="fig">C</xref>, <xref rid="Fig8" ref-type="fig">E</xref>, <xref rid="Fig8" ref-type="fig">F</xref>). It can be seen that M1/M2-type macrophages can upregulate the mRNA and protein expression of PD-L1 in SiHa and HeLa cells. In brief, for M1/M2-type macrophages, there was a consistent effect on increasing the expression levels of PD-L1 mRNA and protein in SiHa cells, and a significant effect on promoting the expression of PD-L1-mRNA in HeLa cells. In addition, compared with M1-type macrophages, M2-type macrophages significantly promoted the expression of PD-L1 mRNA and protein in HeLa cells.<fig id="Fig8"><label>Fig.&#x000a0;8</label><caption><p>M1/M2-type macrophages can promote the expression of PD-L1 in cervical cancer cells. <bold>A</bold> The mRNA expression level of PD-L1 for SiHa after co-culturing with M1/M2-type macrophages. <bold>B</bold> Flow cytometry of PD-L1 expression in SiHa cells. <bold>C</bold> The protein expression level of PD-L1 for SiHa after co-culturing with M1/M2-type macrophages. <bold>D</bold> The mRNA expression level of PD-L1 for HeLa after co-culturing with M1/M2-type macrophages. <bold>E</bold> Flow cytometry of PD-L1 expression in HeLa cells. <bold>F</bold> The protein expression level of PD-L1 for HeLa after co-culturing with M1/M2-type macrophages. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="40001_2024_1897_Fig8_HTML" id="MO8"/></fig></p></sec><sec id="Sec19"><title>M2-type macrophages promote PD-L1 expression in CC cells through the PI3K/AKT pathway</title><p id="Par49">PI3K inhibitor (LY294002) was added to observe the expression of PD-L1 in different groups. After pre-treatment with LY294002 for 1&#x000a0;h, SiHa and HeLa cells were co-cultured with M2-type macrophages. Compared with the control group (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>A, D), the mRNA expression level of PD-L1 in SiHa and HeLa cells was significantly decreased after adding LY294002 inhibitor (<italic>p</italic>&#x02009;=&#x02009;0.0058, <italic>p</italic>&#x02009;=&#x02009;0.0006). The mRNA level of PD-L1 in SiHa and HeLa cells was significantly increased after co-culture with M2-type macrophages (<italic>p</italic>&#x02009;=&#x02009;0.0058, <italic>p</italic>&#x02009;=&#x02009;0.0410), while the results were partially reversed after treatment with LY294002. The expression of PD-L1-mRNA was lower than that in co-culture group and close to the control group (<italic>p</italic>&#x02009;=&#x02009;0.0140, <italic>p</italic>&#x02009;=&#x02009;0.0410). It was also consistent in the protein expression of PD-L1 (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>B, C and E, F). The protein level of PD-L1 in SiHa and HeLa cells was upregulated after co-culture with M2-type macrophages (<italic>p</italic>&#x02009;=&#x02009;0.0078, <italic>p</italic>&#x02009;=&#x02009;0.0287). After being treated with LY294002, the promotion effect of M2-type macrophages on PD-L1 expression in SiHa and HeLa cells was partially reversed, that is, the protein expression of PD-L1 was lower than that in co-culture group (<italic>p</italic>&#x02009;=&#x02009;0.5353, <italic>p</italic>&#x02009;=&#x02009;0.0388). In conclusion, the PI3K inhibitor (LY294002) can reduce mRNA and protein expression of PD-L1 in SiHa and HeLa cells co-cultured with M2-type macrophages. Hence, M2-type macrophages may upregulate the PD-L1 expression of SiHa and HeLa cells through PI3K/AKT pathway.<fig id="Fig9"><label>Fig.&#x000a0;9</label><caption><p>Effect of PI3K inhibitor on PD-L1 expression in cervical cancer cells. <bold>A</bold> The mRNA expression level of PD-L1 in SiHa cells. <bold>B</bold> Flow cytometry of PD-L1 expression in SiHa cells. <bold>C</bold> The protein expression level of PD-L1 in SiHa cells. <bold>D</bold> The mRNA expression level of PD-L1 in HeLa cells. <bold>E</bold> Flow cytometry of PD-L1 expression in HeLa cells. <bold>F</bold> The protein expression level of PD-L1 in HeLa cells. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="40001_2024_1897_Fig9_HTML" id="MO9"/></fig></p></sec></sec><sec id="Sec20"><title>Discussion</title><p id="Par50">CC is the fourth most common female cancer in the world. Currently, through vaccination and regular screening, the occurrence of CC can be effectively prevented. Therefore, the survival rate has been significantly improved through early detection and treatment. However, CC remains a killer in low- and middle-income areas for women who are partially advanced stage when diagnosed with limited treatment options due to limited resources [<xref ref-type="bibr" rid="CR23">23</xref>]. Pembrolizumab approved by the FDA in 2018 has brought hope to patients with advanced CC and improved the curative effect of patients. But the patient response rate was lower than 30% [<xref ref-type="bibr" rid="CR9">9</xref>], which was considered to be associated with immunosuppressive components of TME. TAM, as an immune cell, was involved in the formation of tumor suppressive microenvironment. Therefore, it will provide a new idea for improving patient efficacy and adopting combination therapy about exploring the regulatory mechanism of TAMs on PD-L1.</p><p id="Par51">The expression of PD-L1 was gradually upregulated in normal cervix, cervical intraepithelial neoplasia and CC tissues. And 34.4&#x02013;68.0% of PD-L1 positive expression was detected in tissues of CC patients [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. In our study, 52% of patients with CC showed positive expression of PD-L1 on tumor cells, and 45.9% of CC patients showed PD-L1-positive expression on stromal cells. Hence, it provided a potential therapeutic target for the use of PD-1/PD-L1 inhibitors because of the widespread expression of PD-L1 in tumor tissues. The expression range of PD-L1 was relatively wide due to the differences in patients' clinical characteristics, antibody sources, detection platforms, and evaluation criteria, so we believed that there was valid for the positive rate of PD-L1 in this study. Meanwhile, the expression of PD-L1 in CC tissues was related to fertility history, abortion history, differentiation grade, tumor size and FIGO stage in our study. Previous studies have shown that PD-1/PD-L1 pathway was closely associated with the history of fertility and abortion [<xref ref-type="bibr" rid="CR26">26</xref>]. Pregnancy changed the immune status of the body, especially the uterine microenvironment including the cervix, while activating PD-1/PD-L1 pathways to induce and maintain immune tolerance. Moreover, PD-L1 expression tends to be higher in patients with advanced stage [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], large tumor size [<xref ref-type="bibr" rid="CR29">29</xref>], and poorly differentiated tumors. In summary, these results indicated that the variable efficacy of PD-1/PD-L1 inhibitor therapy may be due to individual differences and different degrees of disease development.</p><p id="Par52">PD-L1 expressed on the surface of tumor cells can lead to T cell apoptosis and invalidation through specifically binding to PD-1 on the surface of tumor-infiltrating T cells, which is an important factor for tumor progression and poor prognosis. Previous studies have also shown that high expression of PD-L1 was associated with poor prognosis in various malignant tumors [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. In CC, the high expression of PD-L1 in tumor tissues was similarly related to poor prognosis [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. In our study, the positive expression of PD-L1 on tumor cells in CC tissue indicated a poor prognosis, while PD-L1 expression on stromal cells was not directly related to the prognosis of patients, suggesting that the expression of PD-L1 on tumor cells in CC TME was a reliable prognostic predictor.</p><p id="Par53">The low response rate of PD-1/PD-L1 immunotherapy in patients with CC may be due to the body's self-resistance to PD-1/PD-L1 inhibitors [<xref ref-type="bibr" rid="CR9">9</xref>], including the loss of new tumor antigens in mismatch repair function, T cell dysfunction caused by T cell exhaustion, and the immunosuppressive components in TME [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. TAMs, as one of the most important immune cells in TME, were generally believed to play a key role in regulating the immunosuppression of PD-1/PD-L1 [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. First of all, macrophages can phagocytose PD&#x02011;1 antibody. Arlauckas et al. observed that PD-1 antibodies could quickly and effectively bind PD-1<sup>+</sup> tumor-infiltrating CD8<sup>+</sup> T cells after administration. However, PD-1<sup>&#x02212;</sup> macrophages can capture PD-1 antibodies from the PD-1<sup>+</sup>CD8<sup>+</sup>T cell surface within minutes, limiting the reactivation of exhausted T cells and rendering them incapable of antitumor effects [<xref ref-type="bibr" rid="CR37">37</xref>]. Furthermore, macrophages inhibited T cells reactivated by PD&#x02011;1 antibody to migrate to tumor islets. T cells must possess some abilities to eradicate tumor cells. On the one hand, they should efficiently accumulate and migrate to interact with tumor cells, on the other hand, T cells must respond adequately to tumor antigens and other activation signals [<xref ref-type="bibr" rid="CR38">38</xref>]. Currently, immunotherapies mainly focus on restoring the dysfunction of T cells [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], but lack of studies on promoting T cells to migrate to tumor nests. CD8<sup>+</sup> T cells poorly migrated and infiltrated into tumor islets resulted from long-lasting interaction with macrophages [<xref ref-type="bibr" rid="CR38">38</xref>]. Therefore, macrophages depletion may reactivate CD8<sup>+</sup>T cells to migrate and invade tumor islets, and improve the therapeutic effect of PD-1/PD-L1 inhibitors. Thirdly, TAMs are capable of secreting cytokines such as TGF-&#x003b2;, prostaglandin E2 (PGE2) and CCL18, which mediate tumor-promoting activity and immunosuppression in the TME. Cytokines secreted by TAMs including TGF-&#x003b2; have been found to affect PD-L1 expression [<xref ref-type="bibr" rid="CR41">41</xref>]. In breast cancer and melanoma, TGF-&#x003b2; can induce the upregulation of PD-L1 in tumor cells and tumor-associated angiogenesis [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Moreover, TGF-&#x003b2; derived from TAMs inhibited T cell activity through phosphorylating Smad2/3 protein and inhibiting mitochondrial respiration, thus promoting the formation of tumor immunosuppressive microenvironment [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. In addition, PGE2 upregulated PD-L1 expression in ovarian cancer cells via activating the PI3K-AKT-mTOR pathway to influence tumor growth [<xref ref-type="bibr" rid="CR17">17</xref>], while reducing the infiltration of CD8<sup>+</sup>T cells [<xref ref-type="bibr" rid="CR18">18</xref>]. Similarly, Wang et al.'s analysis showed that the upregulation of CCL18 secreted by M2-type macrophages can activate the PI3K-AKT pathway, thereby affecting tumor proliferation [<xref ref-type="bibr" rid="CR45">45</xref>]. Therefore, the role of TAMs in the formation of tumor immunosuppressive microenvironment cannot be ignored. In short, macrophages play an important role in the treatment of PD-1/PD-L1. It will lay a theoretical foundation for improving the curative effect of combination therapy in patients by paying attention to the regulatory mechanism of TAMs on PD-1/PD-L1.</p><p id="Par54">Inflammatory cells comprise a high proportion of the tumor context, among which macrophages, also known as TAMs, are one of the most abundant components in the TME [<xref ref-type="bibr" rid="CR46">46</xref>]. As an important group of inflammatory cells in the TME, macrophages are well known for their plasticity and heterogeneity [<xref ref-type="bibr" rid="CR47">47</xref>]. According to the different stimulating factors and secreted products, macrophages subpopulations are traditionally classified into classic activated macrophages (M1) and alternative activated macrophages (M2) [<xref ref-type="bibr" rid="CR46">46</xref>]. However, on account of macrophages can express overlapping M1 and M2 genes, this nomenclature is too simple to label macrophages with M1 or M2 [<xref ref-type="bibr" rid="CR48">48</xref>]. Macrophages perform pro-inflammatory and tumor suppressive functions under the exposure of pro-inflammatory stimuli including IFN-&#x003b3; and lipopolysaccharide (LPS). Specifically, macrophages can contribute to antitumor immunity by releasing IL-1&#x003b2;, IL-12, IL-23, TNF-&#x003b1; and reactive nitrogen [<xref ref-type="bibr" rid="CR13">13</xref>]. While in the TME, macrophages are induced to present the alternatively activated characteristics. High levels of IL-10 and the expression of mannose and galactose receptors which are secreted by macrophages are induced by anti-inflammatory stimuli including IL-4, IL-13 and immune complexes [<xref ref-type="bibr" rid="CR49">49</xref>]. Such macrophages express high levels of Arg-1, TGF-&#x003b2;, and IL-10, which play an anti-inflammatory role and promote tumor cell proliferation, metastasis, angiogenesis and intravasation [<xref ref-type="bibr" rid="CR13">13</xref>]. Under different signal stimulation, M1-type TAMs and M2-type TAMs play a dynamic change [<xref ref-type="bibr" rid="CR50">50</xref>]. Therefore, the origin, the stimuli and the phenotype should be together to define macrophages [<xref ref-type="bibr" rid="CR4">4</xref>]. In the study of Lai and Lv et al., LPS and IFN-&#x003b3; were added to obtain M1-type TAMs, and M2-type TAMs were obtained by adding IL-4 and lL-13 [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. THP-1 cells were differentiated by exposure to PMA followed by addition of human recombinant IFN-&#x003b3;&#x02009;+&#x02009;LPS and IL-4 to obtain M1-type and M2-type TAMs, respectively [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Similarly, in our study, M1-type and M2-type TAMs were obtained by IFN-r&#x02009;+&#x02009;LPS and IL-4&#x02009;+&#x02009;IL-13, respectively. The changes in cell morphology were consistent with the descriptions in previous study. And the characteristic markers of M1-type TAMs showed high expression of TNF-a and IL-1&#x003b2;, and M2-type TAMs highly expressed TGF-&#x003b2; and CD163, which further confirmed the M1/M2-type TAMs model obtained by induced differentiation. It laid a foundation for the subsequent cell experiments in vitro.</p><p id="Par55">Through establishing the co-culture system of TAMs and tumor cells, the effect of TAMs on CC cells morphology was initially observed. There were significant changes in cell morphology after co-culturing with M1/M2-type TAMs, especially after co-culturing with M2-type TAMs. This was similar to the results of Chiu et al. and Ni et al. The morphology of oral squamous carcinoma cell was altered and intercellular tight junctions were disappeared after co-culturing with M2-type TAMs [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. In addition, the migration and invasion ability of tumor cells was enhanced by co-culturing with TAMs [<xref ref-type="bibr" rid="CR57">57</xref>], which also reached a consistent conclusion in studies on gastric cancer cells and lung cancer cells [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. In our study, compared with the non-co-culture group, the migration and invasion ability of SiHa and HeLa cells were significantly enhanced in the co-culture group, especially after co-culture with M2-type TAMs. Hence, the above results indicated that TAMs can affect the morphology of CC cells, enhance the migration and invasion ability of CC cells, and lead to tumor progression, especially after co-culturing with M2-type TAMs.</p><p id="Par56">There was a high correlation between the infiltration of TAMs and PD-L1 expression. CD68 is a marker for pan-macrophages. CD163 is considered as a specific molecular marker for M2-type TAMs. In the study of Deng et al., the density of CD68<sup>+</sup> and CD163<sup>+</sup> macrophages in PD-L1-positive nasopharyngeal carcinoma tissues was significantly higher than that in PD-L1-negative tissues [<xref ref-type="bibr" rid="CR60">60</xref>]. Similarly, in the study of Harada et al., the intratumoral infiltration of CD68<sup>+</sup> and CD163<sup>+</sup> macrophages were significantly higher in gastric adenocarcinoma tissues with PD-L1-positive than in those PD-L1-negative [<xref ref-type="bibr" rid="CR61">61</xref>]. In the study of Guo et al., it was reached a consistent conclusion in CC tissues. In this study, PD-L1 expression was positively correlated with the infiltration of CD68<sup>+</sup> and CD163<sup>+</sup> macrophages by performing IHC staining of 98 patients. Meanwhile, through GSVA and correlation analysis of TCGA-CESC data, it was found that PD-L1 was correlated with M1/M2-type TAMs and positively correlated with TAMs-related CD molecules and cytokines. And the correlation between M1-type macrophages and PD-L1 seems to be stronger than M2 macrophages in the TCGA-CESC data. Unfortunately, this is in conflict with the results of in vitro cell experiments, where M2-type macrophages have a more significant impact on tumor cells. There are several factors. Firstly, M1/M2-type macrophages were represented by characteristic molecules rather than actual macrophages in GSVA analyses. Therefore, there is a direct impact on the results for the selection of characteristic molecules. Secondly, in the correlation analysis between the expression of PD-L1 and CD molecules, we only selected representative TAMs-related CD molecules that were currently undisputed, resulting in contradictory results compared to in vitro experiments. In fact, different choices of CD molecules may result in different outcomes. In addition, PD-L1 expression was weakly correlated with most TAMs-elated cytokines, which should not be ignored that some cytokines were secreted to the periphery and did not exist in tissues. Furthermore, many of these cytokines share expression with other cells present in the inflammatory infiltrate of CC tissue, so the cytokines involved in our study are not specific and cannot determine the role of macrophages through such correlation analysis. Therefore, these findings provide preliminary support for a potential interaction between TAMs and PD-L1, which still needs to be further validated in practice.</p><p id="Par57">At present, the combination therapy of PD-1/PD-L1 inhibitors and targeted TAMs has made certain achievements. The TGF-&#x003b2; inhibitors and colony-stimulating factor 1 receptor (CSF-1R) inhibitor were widely recognized targeted TAMs therapy [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. The combination therapy of TGF-&#x003b2; inhibitors (1D11 and galunisertib) and anti-PD-1/PD-L1 can upregulate the expression of immune response genes, restore the cytotoxic activity of T cells and antitumor activity of anti-PD-L1 [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Tranilast, another TGF-&#x003b2; inhibitor, combined with anti-PD-1/PD-L1 can enhance the infiltration of M1-type TAMs in tumor tissues, thus improving the anti-PD-L1 efficacy [<xref ref-type="bibr" rid="CR65">65</xref>]. CSF-1R inhibitor PLX3397 (pexidartinib) combined with PD-1 therapy showed a synergistic therapeutic effect in increasing the infiltration of CD8<sup>+</sup>T cells to improve antitumor efficacy [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. And it can also effectively reduce the occurrence of tumor neovascularization and ascites [<xref ref-type="bibr" rid="CR67">67</xref>]. BLZ945 (CSF-1R inhibitor) can also effectively control tumor growth when combined with PD-1/PD-L1 blocking antibody [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Therefore, the combination of targeted TAMs therapy with anti-PD-1/PD-L1 improves the efficacy of cancer treatment, while clearing the regulation of PD-L1 expression on tumor cells by TAMs is particularly important for combination therapy.</p><p id="Par58">The regulatory mechanism of TAMs on PD-L1 has been reported in some solid tumors. Through co-culturing with tumor cells in vitro, M2-type TAMs could promote PD-L1 expression on breast cancer cells and esophageal cancer cells to affect tumor progress [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Further, TAMs can induce PD-L1 expression on tumor cells through activating the PI3K/AKT pathway in ovarian cancer and lung cancer, thereby affecting tumor growth and drug efficacy, respectively [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Therefore, tumor-infiltrating TAMs were involved in the regulation of PD-L1 on tumor cells via PI3K/AKT pathway. In our study, TAMs can increase the mRNA and protein levels of PD-L1 on CC cells. Moreover, M2-type TAMs can upregulate the expression of PD-L1 through the PI3K/AKT pathway. The effect of the PI3K/AKT pathway on immune cells and the immune microenvironment is complicated. PI3K/AKT molecules not only affect the expression of PD-L1 in cancer cells [<xref ref-type="bibr" rid="CR71">71</xref>], but also induce the differentiation of macrophages into M2-type, thereby promoting tumor proliferation and reducing cell apoptosis. Specifically, in Wu et al. study, PI3K signal transduction upregulated HIF-1a expression to induce macrophage polarization, resulting in cancer cell migration, invasion and metastasis [<xref ref-type="bibr" rid="CR72">72</xref>]. In addition, M2 macrophage polarization was induced via activation of the PI3K/AKT signaling pathway, which promoted CRC metastasis [<xref ref-type="bibr" rid="CR73">73</xref>]. Therefore, on the one hand, TAMs induced the activation of PI3K/AKT signaling pathway in tumor cells to upregulate the expression of immune escape molecules; on the other hand, TAMs was influenced by PI3K/AKT pathway and its products to further promote tumor proliferation and metastasis.</p><p id="Par59">TAMs and tumor cells are closely related in the TME. This study found that TAMs can affect tumor cell morphology, function and immune checkpoint expression, thereby exerting immunosuppressive effects, which may be partly responsible for resistance to PD-1/PD-L1 therapy. Therefore, this study provided a theoretical basis for the combination therapy of TAMs with PD-1/PD-L1 by exploring the mechanism for PD-L1 expression regulated by TAMs. However, the present study still has some shortcomings. Firstly, due to the limitation of paraffin-embedded specimens, the expression and correlation of PD-L1, CD68 and CD163 should be explored in a larger population cohort. Secondly, this study explored the effects of TAMs on the morphology, function and the expression of PD-L1 on tumor cells by constructing a co-culture system. But the relationship between alterations in cell morphology and function and PD-L1 expression was ignored. We could not determine whether the changes of cell morphology and function affected PD-L1 expression, or whether the expression of PD-L1 changed the cell morphology and function, or whether there was no relationship between them. It needs to be further explored. Thirdly, in this study, M2-type TAMs obviously increased PD-L1 expression of CC tumor cells, significantly changed the morphology of tumor cells, and increased their migration and invasion functions. Combined with previous studies, M2-type TAMs often acted as an adverse factor to promote tumor growth and often formed a tumor suppressive microenvironment that affected the treatment of PD-L1. Therefore, we only focused on the regulatory mechanism of M2-type TAMs on CC cells, while studies on the regulatory mechanism of M1-type TAMs on PD-L1 was lacking. Meanwhile, it was not comprehensive enough for the regulatory mechanism of PD-L1 expression on CC cells by M2-type TAMs, and was also lacking animal experiments. We will focus on using different methods to confirm the molecular changes of pathway in future research and establishing the animal model for in vivo experiments to improve the study.</p></sec><sec id="Sec21"><title>Conclusion</title><p id="Par60">In conclusion, PD-L1 was positively expressed on tumor cells in 52% of CC patients, and could be used as a prognostic predictor, and was closely related to CD163<sup>+</sup>TAMs infiltration. In addition, TAMs can affect the morphology of CC cells and enhance cell migration and invasion ability. M2-type TAMs may upregulate the expression of PD-L1 on CC cells through PI3K/AKT pathway, thus affecting the progression of tumor. In conclusion, studying the regulatory mechanism of TAMs on PD-L1 expression in CC cells provided a theoretical basis for improving patient efficacy and combined therapy.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CC</term><def><p id="Par5">Cervical cancer</p></def></def-item><def-item><term>TME</term><def><p id="Par6">Tumor microenvironment</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par7">Programmed cell death ligand 1</p></def></def-item><def-item><term>PD-1</term><def><p id="Par8">Programmed cell death factor 1</p></def></def-item><def-item><term>ICIs</term><def><p id="Par9">Immune checkpoint inhibitors</p></def></def-item><def-item><term>ORR</term><def><p id="Par10">Objective response rate</p></def></def-item><def-item><term>IL</term><def><p id="Par11">Interleukin</p></def></def-item><def-item><term>CSF-1</term><def><p id="Par12">Colony-stimulating factor 1</p></def></def-item><def-item><term>Arg</term><def><p id="Par13">Arginnse-1</p></def></def-item><def-item><term>PI3K/AKT</term><def><p id="Par14">Phosphatidylinositol 3-Kinase/protein kinase B</p></def></def-item><def-item><term>IHC</term><def><p id="Par15">Immunohistochemistry</p></def></def-item><def-item><term>qRT-PCR</term><def><p id="Par16">Quantitative real-time PCR</p></def></def-item><def-item><term>GSVA</term><def><p id="Par17">Gene setvariation analysis</p></def></def-item><def-item><term>IFN-&#x003b3;</term><def><p id="Par18">Interferon-r</p></def></def-item><def-item><term>TNF-&#x003b1;</term><def><p id="Par19">Tumor necrosis factor &#x003b1;</p></def></def-item><def-item><term>TGF-&#x003b2;</term><def><p id="Par20">Transforming growing factor &#x003b2;</p></def></def-item><def-item><term>CSF-1R</term><def><p id="Par21">Colony-stimulating factor 1 receptor</p></def></def-item><def-item><term>LPS</term><def><p id="Par22">Lipopolysaccharide</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Fan Guo, Weina Kong and Dewei Li contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Thanks to Xinjiang Medical University for providing the experimental platform and helping the authors with the manuscript. And we sincerely thank all the authors and study participants for their support in this study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>FG, WNK and DWL contributed equally to this work. FG and WNK designed the study and wrote the paper. WNK and DWL performed most of the experiments and data analysis. GZ, MA and FFX analyzed the data and revised the paper. YMZ visualized the data. CLM and XMM supervised the review and editing of manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by Grants from the special scientific research project of young medical scientific and technological talents of Xinjiang Uygur Autonomous region Health and Family Planning Commission (WJWY-202403), the "Tianchi Excellence" Program of Xinjiang Uygur Autonomous region (2022TCYCGF), the Talent Support Project of the Tumor Hospital Affiliated to Xinjiang Medical University (2021KX002), the Postdoctoral Fund of Tumor Hospital Affiliated to Xinjiang Medical University, the Excellent Postdoctoral Program of Xinjiang Uygur Autonomous Region, and Natural Science Foundation of Xinjiang Uygur Autonomous region (2021D01C402).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>All data generated or analyzed during this study are included in this published article.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par61">The study was approved by the Ethics Committee of The Tumor Hospital Affiliated to Xinjiang Medical University (ethics approval ID: G-2023020).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par62">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par63">The authors declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutlu</surname><given-names>L</given-names></name><name><surname>Tymon-Rosario</surname><given-names>J</given-names></name><name><surname>Harold</surname><given-names>J</given-names></name><etal/></person-group><article-title>Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer</article-title><source>Expert Rev Anticancer Ther</source><year>2022</year><volume>22</volume><issue>6</issue><fpage>633</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1080/14737140.2022.2075348</pub-id><?supplied-pmid 35533682?><pub-id pub-id-type="pmid">35533682</pub-id>
</element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>W Jr</given-names></name><name><surname>Bacon</surname><given-names>MA</given-names></name><name><surname>Bajaj</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cervical cancer: A global health crisis</article-title><source>Cancer</source><year>2017</year><volume>123</volume><issue>13</issue><fpage>2404</fpage><lpage>2412</lpage><pub-id pub-id-type="doi">10.1002/cncr.30667</pub-id><?supplied-pmid 28464289?><pub-id pub-id-type="pmid">28464289</pub-id>
</element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Analysis of therapeutic targets and prognostic biomarkers of CXC chemokines in cervical cancer microenvironment</article-title><source>Cancer Cell Int</source><year>2021</year><volume>21</volume><issue>1</issue><fpage>399</fpage><pub-id pub-id-type="doi">10.1186/s12935-021-02101-9</pub-id><?supplied-pmid 34321012?><pub-id pub-id-type="pmid">34321012</pub-id>
</element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagabu</surname><given-names>M</given-names></name><name><surname>Nagasawa</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>C</given-names></name><etal/></person-group><article-title>Immunotherapy for uterine cervical cancer using checkpoint inhibitors: future directions</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><issue>7</issue><fpage>2335</fpage><pub-id pub-id-type="doi">10.3390/ijms21072335</pub-id><?supplied-pmid 32230938?><pub-id pub-id-type="pmid">32230938</pub-id>
</element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niyazi</surname><given-names>M</given-names></name><name><surname>Sui</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Correlation between Methylation of Human Papillomavirus-16 L1 Gene and Cervical Carcinoma in Uyghur Women</article-title><source>Gynecol Obstet Invest</source><year>2017</year><volume>82</volume><issue>1</issue><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1159/000444585</pub-id><?supplied-pmid 26954462?><pub-id pub-id-type="pmid">26954462</pub-id>
</element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Qi</surname><given-names>Q</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><etal/></person-group><article-title>The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer</article-title><source>J Cancer Res Clin Oncol</source><year>2019</year><volume>145</volume><issue>6</issue><fpage>1377</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1007/s00432-019-02879-2</pub-id><?supplied-pmid 30963235?><pub-id pub-id-type="pmid">30963235</pub-id>
</element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>PA</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Piha-Paul</surname><given-names>SA</given-names></name><etal/></person-group><article-title>T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><issue>4</issue><fpage>318</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1200/JCO.2018.78.2276</pub-id><?supplied-pmid 30557521?><pub-id pub-id-type="pmid">30557521</pub-id>
</element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>HC</given-names></name><name><surname>Ros</surname><given-names>W</given-names></name><name><surname>Delord</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><issue>17</issue><fpage>1470</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1200/JCO.18.01265</pub-id><?supplied-pmid 30943124?><pub-id pub-id-type="pmid">30943124</pub-id>
</element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrall</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>KY</given-names></name><name><surname>Roden</surname><given-names>RBS</given-names></name><etal/></person-group><article-title>Cervical cancer immunotherapy: facts and hopes</article-title><source>Clin Cancer Res</source><year>2021</year><volume>27</volume><issue>18</issue><fpage>4953</fpage><lpage>4973</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-2833</pub-id><?supplied-pmid 33888488?><pub-id pub-id-type="pmid">33888488</pub-id>
</element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tumor-associated macrophages: recent insights and therapies</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>188</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.00188</pub-id><?supplied-pmid 32161718?><pub-id pub-id-type="pmid">32161718</pub-id>
</element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotechini</surname><given-names>T</given-names></name><name><surname>Atallah</surname><given-names>A</given-names></name><name><surname>Grossman</surname><given-names>A</given-names></name></person-group><article-title>Tissue-resident and recruited macrophages in primary tumor and metastatic microenvironments: potential targets in cancer therapy</article-title><source>Cells</source><year>2021</year><volume>10</volume><issue>4</issue><fpage>960</fpage><pub-id pub-id-type="doi">10.3390/cells10040960</pub-id><?supplied-pmid 33924237?><pub-id pub-id-type="pmid">33924237</pub-id>
</element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zhi</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>BP</given-names></name><etal/></person-group><article-title>The role of tumor associated macrophages in the tumor microenvironment: mechanism and functions</article-title><source>Anticancer Agents Med Chem</source><year>2016</year><volume>16</volume><issue>9</issue><fpage>1133</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.2174/1871520616666160520112622</pub-id><?supplied-pmid 27198986?><pub-id pub-id-type="pmid">27198986</pub-id>
</element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Carlos</surname><given-names>CJJ</given-names></name><etal/></person-group><article-title>Research progress of tumor microenvironment and tumor-associated macrophages</article-title><source>Clin Transl Oncol</source><year>2020</year><volume>22</volume><issue>12</issue><fpage>2141</fpage><lpage>2152</lpage><pub-id pub-id-type="doi">10.1007/s12094-020-02367-x</pub-id><?supplied-pmid 32447645?><pub-id pub-id-type="pmid">32447645</pub-id>
</element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukamoto</surname><given-names>M</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Ishimoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-alpha leads to poor pancreatic cancer prognosis</article-title><source>Cancer Sci</source><year>2019</year><volume>110</volume><issue>1</issue><fpage>310</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1111/cas.13874</pub-id><?supplied-pmid 30426611?><pub-id pub-id-type="pmid">30426611</pub-id>
</element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shima</surname><given-names>T</given-names></name><name><surname>Shimoda</surname><given-names>M</given-names></name><name><surname>Shigenobu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma</article-title><source>Cancer Sci</source><year>2020</year><volume>111</volume><issue>2</issue><fpage>727</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1111/cas.14272</pub-id><?supplied-pmid 31821665?><pub-id pub-id-type="pmid">31821665</pub-id>
</element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>V</given-names></name><name><surname>Eykyn</surname><given-names>TR</given-names></name><name><surname>Mustapha</surname><given-names>R</given-names></name><etal/></person-group><article-title>Breast cancer-associated macrophages promote tumorigenesis by suppressing succinate dehydrogenase in tumor cells</article-title><source>Sci Signal.</source><year>2020</year><volume>13</volume><issue>652</issue><fpage>eaax4585</fpage><pub-id pub-id-type="doi">10.1126/scisignal.aax4585</pub-id><?supplied-pmid 33023985?><pub-id pub-id-type="pmid">33023985</pub-id>
</element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komura</surname><given-names>N</given-names></name><name><surname>Mabuchi</surname><given-names>S</given-names></name><name><surname>Shimura</surname><given-names>K</given-names></name><etal/></person-group><article-title>The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer</article-title><source>Cancer Immunol Immunother</source><year>2020</year><volume>69</volume><issue>12</issue><fpage>2477</fpage><lpage>2499</lpage><pub-id pub-id-type="doi">10.1007/s00262-020-02628-2</pub-id><?supplied-pmid 32561967?><pub-id pub-id-type="pmid">32561967</pub-id>
</element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>PD-L1 induced by IFN-gamma from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer</article-title><source>Int J Clin Oncol</source><year>2017</year><volume>22</volume><issue>6</issue><fpage>1026</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1007/s10147-017-1161-7</pub-id><?supplied-pmid 28748356?><pub-id pub-id-type="pmid">28748356</pub-id>
</element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Feng</surname><given-names>YC</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><etal/></person-group><article-title>Tumor-Associated CD163<sup>+</sup> M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer</article-title><source>Cancer Manag Res</source><year>2020</year><volume>12</volume><fpage>5831</fpage><lpage>5843</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S257692</pub-id><?supplied-pmid 32765086?><pub-id pub-id-type="pmid">32765086</pub-id>
</element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahrami</surname><given-names>A</given-names></name><name><surname>Hasanzadeh</surname><given-names>M</given-names></name><name><surname>Hassanian</surname><given-names>SM</given-names></name><etal/></person-group><article-title>The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy</article-title><source>J Cell Biochem</source><year>2017</year><volume>118</volume><issue>12</issue><fpage>4163</fpage><lpage>4169</lpage><pub-id pub-id-type="doi">10.1002/jcb.26118</pub-id><?supplied-pmid 28475243?><pub-id pub-id-type="pmid">28475243</pub-id>
</element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>PJ</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Biswas</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Macrophage activation and polarization: nomenclature and experimental guidelines</article-title><source>Immunity</source><year>2014</year><volume>41</volume><issue>1</issue><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.008</pub-id><?supplied-pmid 25035950?><pub-id pub-id-type="pmid">25035950</pub-id>
</element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><etal/></person-group><article-title>PD-L1-mediated immunosuppression in glioblastoma is associated with the infiltration and M2-polarization of tumor-associated macrophages</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>588552</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.588552</pub-id><?supplied-pmid 33329573?><pub-id pub-id-type="pmid">33329573</pub-id>
</element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burmeister</surname><given-names>CA</given-names></name><name><surname>Khan</surname><given-names>SF</given-names></name><name><surname>Sch&#x000e4;fer G</surname><given-names>G</given-names></name><etal/></person-group><article-title>Cervical cancer therapies: current challenges and future perspectives</article-title><source>Tumour Virus Res</source><year>2022</year><volume>13</volume><fpage>200238</fpage><pub-id pub-id-type="doi">10.1016/j.tvr.2022.200238</pub-id><?supplied-pmid 35460940?><pub-id pub-id-type="pmid">35460940</pub-id>
</element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>OL</given-names></name><name><surname>Shintaku</surname><given-names>PI</given-names></name><name><surname>Moatamed</surname><given-names>NA</given-names></name></person-group><article-title>Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas</article-title><source>Diagn Pathol</source><year>2017</year><volume>12</volume><issue>1</issue><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/s13000-017-0631-6</pub-id><?supplied-pmid 28623908?><pub-id pub-id-type="pmid">28623908</pub-id>
</element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><etal/></person-group><article-title>PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: from bench to bed</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>849352</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.849352</pub-id><?supplied-pmid 36313730?><pub-id pub-id-type="pmid">36313730</pub-id>
</element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>YC</given-names></name><name><surname>Ji</surname><given-names>WL</given-names></name><name><surname>Yue</surname><given-names>N</given-names></name><etal/></person-group><article-title>The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance</article-title><source>Cancer Manag Res</source><year>2018</year><volume>10</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S152232</pub-id><?supplied-pmid 29403308?><pub-id pub-id-type="pmid">29403308</pub-id>
</element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><etal/></person-group><article-title>PD-L1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer</article-title><source>J Cancer</source><year>2018</year><volume>9</volume><issue>16</issue><fpage>2938</fpage><lpage>2945</lpage><pub-id pub-id-type="doi">10.7150/jca.22532</pub-id><?supplied-pmid 30123362?><pub-id pub-id-type="pmid">30123362</pub-id>
</element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heeren</surname><given-names>AM</given-names></name><name><surname>Punt</surname><given-names>S</given-names></name><name><surname>Bleeker</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix</article-title><source>Mod Pathol</source><year>2016</year><volume>29</volume><issue>7</issue><fpage>753</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2016.64</pub-id><?supplied-pmid 27056074?><pub-id pub-id-type="pmid">27056074</pub-id>
</element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saglam</surname><given-names>O</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>PD-L1 Expression Correlates With Young Age and CD8+ TIL density in poorly differentiated cervical squamous cell carcinoma</article-title><source>Int J Gynecol Pathol</source><year>2020</year><volume>39</volume><issue>5</issue><fpage>428</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1097/PGP.0000000000000623</pub-id><?supplied-pmid 31274701?><pub-id pub-id-type="pmid">31274701</pub-id>
</element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noronha</surname><given-names>C</given-names></name><name><surname>Ribeiro</surname><given-names>AS</given-names></name><name><surname>Taipa</surname><given-names>R</given-names></name><etal/></person-group><article-title>PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma</article-title><source>J Neurooncol</source><year>2022</year><volume>156</volume><issue>3</issue><fpage>453</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1007/s11060-021-03907-3</pub-id><?supplied-pmid 35066764?><pub-id pub-id-type="pmid">35066764</pub-id>
</element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumitomo</surname><given-names>R</given-names></name><name><surname>Hirai</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><etal/></person-group><article-title>PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer</article-title><source>Lung Cancer</source><year>2019</year><volume>136</volume><fpage>136</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2019.08.023</pub-id><?supplied-pmid 31499335?><pub-id pub-id-type="pmid">31499335</pub-id>
</element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Relationship and prognostic significance of IL-33, PD-1/PD-L1, and tertiary lymphoid structures in cervical cancer</article-title><source>J Leukoc Biol</source><year>2022</year><volume>112</volume><issue>6</issue><fpage>1591</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.1002/JLB.5MA0322-746R</pub-id><?supplied-pmid 35501298?><pub-id pub-id-type="pmid">35501298</pub-id>
</element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Chan</surname><given-names>HL</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name></person-group><article-title>Immune checkpoint inhibitors: basics and challenges</article-title><source>Curr Med Chem</source><year>2019</year><volume>26</volume><issue>17</issue><fpage>3009</fpage><lpage>3025</lpage><pub-id pub-id-type="doi">10.2174/0929867324666170804143706</pub-id><?supplied-pmid 28782469?><pub-id pub-id-type="pmid">28782469</pub-id>
</element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><etal/></person-group><article-title>Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors</article-title><source>Front Cell Dev Biol</source><year>2020</year><volume>8</volume><fpage>672</fpage><pub-id pub-id-type="doi">10.3389/fcell.2020.00672</pub-id><?supplied-pmid 32793604?><pub-id pub-id-type="pmid">32793604</pub-id>
</element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>Q</given-names></name></person-group><article-title>Tumor-associated macrophages regulate PD-1/PD-L1 immunosuppression</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>874589</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.874589</pub-id><?supplied-pmid 35592338?><pub-id pub-id-type="pmid">35592338</pub-id>
</element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitt</surname><given-names>JM</given-names></name><name><surname>Vetizou</surname><given-names>M</given-names></name><name><surname>Daillere</surname><given-names>R</given-names></name><etal/></person-group><article-title>Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors</article-title><source>Immunity</source><year>2016</year><volume>44</volume><issue>6</issue><fpage>1255</fpage><lpage>1269</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.06.001</pub-id><?supplied-pmid 27332730?><pub-id pub-id-type="pmid">27332730</pub-id>
</element-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Arlauckas SP, Garris CS, Kohler RH, et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med. 2017;9 (389):eaal3604.</mixed-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peranzoni</surname><given-names>E</given-names></name><name><surname>Lemoine</surname><given-names>J</given-names></name><name><surname>Vimeux</surname><given-names>L</given-names></name><etal/></person-group><article-title>Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><issue>17</issue><fpage>E4041</fpage><lpage>E4050</lpage><pub-id pub-id-type="doi">10.1073/pnas.1720948115</pub-id><?supplied-pmid 29632196?><pub-id pub-id-type="pmid">29632196</pub-id>
</element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name></person-group><article-title>Elements of cancer immunity and the cancer-immune set point</article-title><source>Nature</source><year>2017</year><volume>541</volume><issue>7637</issue><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/nature21349</pub-id><?supplied-pmid 28102259?><pub-id pub-id-type="pmid">28102259</pub-id>
</element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KG</given-names></name><name><surname>Stromnes</surname><given-names>IM</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name></person-group><article-title>Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies</article-title><source>Cancer Cell</source><year>2017</year><volume>31</volume><issue>3</issue><fpage>311</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.02.008</pub-id><?supplied-pmid 28292435?><pub-id pub-id-type="pmid">28292435</pub-id>
</element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>D</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><issue>15</issue><fpage>7002</fpage><lpage>7014</lpage><pub-id pub-id-type="doi">10.7150/thno.46176</pub-id><?supplied-pmid 32550918?><pub-id pub-id-type="pmid">32550918</pub-id>
</element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Dang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Bidirectional regulation between tumor cell-intrinsic PD-L1 and TGF-&#x003b2;1 in epithelial-to-mesenchymal transition in melanoma</article-title><source>Transl Cancer Res</source><year>2022</year><volume>11</volume><issue>10</issue><fpage>3698</fpage><lpage>3710</lpage><pub-id pub-id-type="doi">10.21037/tcr-22-292</pub-id><?supplied-pmid 36388018?><pub-id pub-id-type="pmid">36388018</pub-id>
</element-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Dimeloe S, Gubser P, Loeliger J, et al. Tumor-derived TGF-beta inhibits mitochondrial respiration to suppress IFN-gamma production by human CD4 (+) T cells. Sci Signal. 2019;12 (599):eaav3334.</mixed-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Impaired T cell function in malignant pleural effusion is caused by TGF-beta derived predominantly from macrophages</article-title><source>Int J Cancer</source><year>2016</year><volume>139</volume><issue>10</issue><fpage>2261</fpage><lpage>2269</lpage><pub-id pub-id-type="doi">10.1002/ijc.30289</pub-id><?supplied-pmid 27459735?><pub-id pub-id-type="pmid">27459735</pub-id>
</element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lyu</surname><given-names>Z</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><issue>25</issue><fpage>11535</fpage><lpage>11548</lpage><pub-id pub-id-type="doi">10.7150/thno.45261</pub-id><?supplied-pmid 33052231?><pub-id pub-id-type="pmid">33052231</pub-id>
</element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>SY</given-names></name><name><surname>Song</surname><given-names>XY</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy</article-title><source>Pharmacol Res</source><year>2020</year><volume>161</volume><fpage>105111</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.105111</pub-id><?supplied-pmid 33065284?><pub-id pub-id-type="pmid">33065284</pub-id>
</element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salah</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Macrophages as a Double-Edged Weapon: The Use of Macrophages in Cancer Immunotherapy and Understanding the Cross-Talk Between Macrophages and Cancer</article-title><source>DNA Cell Biol</source><year>2021</year><volume>40</volume><issue>3</issue><fpage>429</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1089/dna.2020.6087</pub-id><?supplied-pmid 33481665?><pub-id pub-id-type="pmid">33481665</pub-id>
</element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quail</surname><given-names>DF</given-names></name><name><surname>Joyce</surname><given-names>JA</given-names></name></person-group><article-title>Molecular pathways: deciphering mechanisms of resistance to macrophage-targeted therapies</article-title><source>Clin Cancer Res</source><year>2017</year><volume>23</volume><issue>4</issue><fpage>876</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-0133</pub-id><?supplied-pmid 27895033?><pub-id pub-id-type="pmid">27895033</pub-id>
</element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>N</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Shu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Targeting tumor-associated macrophages as an antitumor strategy</article-title><source>Biochem Pharmacol</source><year>2021</year><volume>183</volume><fpage>114354</fpage><pub-id pub-id-type="doi">10.1016/j.bcp.2020.114354</pub-id><?supplied-pmid 33279498?><pub-id pub-id-type="pmid">33279498</pub-id>
</element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Exosomal MicroRNAs as mediators of cellular interactions between cancer cells and macrophages</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>1167</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01167</pub-id><?supplied-pmid 32595638?><pub-id pub-id-type="pmid">32595638</pub-id>
</element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CY</given-names></name><name><surname>Tseng</surname><given-names>PC</given-names></name><name><surname>Chen</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages</article-title><source>J Inflamm Res</source><year>2021</year><volume>14</volume><fpage>5241</fpage><lpage>5249</lpage><pub-id pub-id-type="doi">10.2147/JIR.S329921</pub-id><?supplied-pmid 34675601?><pub-id pub-id-type="pmid">34675601</pub-id>
</element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>FK</given-names></name><etal/></person-group><article-title>M2-like tumour-associated macrophage-secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway</article-title><source>Mol Med Rep</source><year>2021</year><volume>24</volume><issue>2</issue><fpage>604</fpage><pub-id pub-id-type="doi">10.3892/mmr.2021.12249</pub-id><?supplied-pmid 34184083?><pub-id pub-id-type="pmid">34184083</pub-id>
</element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zong</surname><given-names>Z</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Mao</surname><given-names>R</given-names></name><etal/></person-group><article-title>M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1beta Signaling</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>1643</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01643</pub-id><?supplied-pmid 31379842?><pub-id pub-id-type="pmid">31379842</pub-id>
</element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>In vitro-induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells</article-title><source>Exp Cell Res</source><year>2018</year><volume>364</volume><issue>1</issue><fpage>113</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2018.01.041</pub-id><?supplied-pmid 29408565?><pub-id pub-id-type="pmid">29408565</pub-id>
</element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>KC</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Liu</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Polarization of tumor-associated macrophages and Gas6/Axl signaling in oral squamous cell carcinoma</article-title><source>Oral Oncol</source><year>2015</year><volume>51</volume><issue>7</issue><fpage>683</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2015.04.004</pub-id><?supplied-pmid 25910588?><pub-id pub-id-type="pmid">25910588</pub-id>
</element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>YH</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>XF</given-names></name><etal/></person-group><article-title>Microlocalization of CD68+ tumor-associated macrophages in tumor stroma correlated with poor clinical outcomes in oral squamous cell carcinoma patients</article-title><source>Tumour Biol</source><year>2015</year><volume>36</volume><issue>7</issue><fpage>5291</fpage><lpage>5298</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-3189-5</pub-id><?supplied-pmid 25666753?><pub-id pub-id-type="pmid">25666753</pub-id>
</element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimm</surname><given-names>M</given-names></name><name><surname>Feyen</surname><given-names>O</given-names></name><name><surname>Coy</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Analysis of circulating CD14+/CD16+ monocyte-derived macrophages (MDMs) in the peripheral blood of patients with oral squamous cell carcinoma</article-title><source>Oral Surg Oral Med Oral Pathol Oral Radiol</source><year>2016</year><volume>121</volume><issue>3</issue><fpage>301</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1016/j.oooo.2015.10.024</pub-id><?supplied-pmid 26747736?><pub-id pub-id-type="pmid">26747736</pub-id>
</element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Tumor-infiltrating immune cells and prognosis in gastric cancer: a systematic review and meta-analysis</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>37</issue><fpage>62312</fpage><lpage>62329</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.17602</pub-id><?supplied-pmid 28977947?><pub-id pub-id-type="pmid">28977947</pub-id>
</element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Jiao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation</article-title><source>Int J Oncol</source><year>2017</year><volume>51</volume><issue>1</issue><fpage>25</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.3892/ijo.2017.4014</pub-id><?supplied-pmid 28534943?><pub-id pub-id-type="pmid">28534943</pub-id>
</element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>PD-L1 Expression is Highly Associated with Tumor-Associated Macrophage Infiltration in Nasopharyngeal Carcinoma</article-title><source>Cancer Manag Res</source><year>2020</year><volume>12</volume><fpage>11585</fpage><lpage>11596</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S274913</pub-id><?supplied-pmid 33209062?><pub-id pub-id-type="pmid">33209062</pub-id>
</element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harada</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Estrella</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma</article-title><source>Gastric Cancer</source><year>2018</year><volume>21</volume><issue>1</issue><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1007/s10120-017-0760-3</pub-id><?supplied-pmid 28801853?><pub-id pub-id-type="pmid">28801853</pub-id>
</element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariathasan</surname><given-names>S</given-names></name><name><surname>Turley</surname><given-names>SJ</given-names></name><name><surname>Nickles</surname><given-names>D</given-names></name><etal/></person-group><article-title>TGF&#x003b2;&#x00026;nbsp;attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells</article-title><source>Nature</source><year>2018</year><volume>554</volume><issue>7693</issue><fpage>544</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/nature25501</pub-id><?supplied-pmid 29443960?><pub-id pub-id-type="pmid">29443960</pub-id>
</element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Roca</surname><given-names>CA</given-names></name><name><surname>Italiano</surname><given-names>A</given-names></name><name><surname>Le Tourneau</surname><given-names>C</given-names></name><etal/></person-group><article-title>Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages</article-title><source>Ann Oncol</source><year>2019</year><volume>30</volume><issue>8</issue><fpage>1381</fpage><lpage>1392</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz163</pub-id><?supplied-pmid 31114846?><pub-id pub-id-type="pmid">31114846</pub-id>
</element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>YW</given-names></name><name><surname>Coles</surname><given-names>GL</given-names></name><name><surname>Sandhu</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Single-cell transcriptomics reveals the effect of PD-L1/TGF-beta blockade on the tumor microenvironment</article-title><source>BMC Biol</source><year>2021</year><volume>19</volume><issue>1</issue><fpage>107</fpage><pub-id pub-id-type="doi">10.1186/s12915-021-01034-z</pub-id><?supplied-pmid 34030676?><pub-id pub-id-type="pmid">34030676</pub-id>
</element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panagi</surname><given-names>M</given-names></name><name><surname>Voutouri</surname><given-names>C</given-names></name><name><surname>Mpekris</surname><given-names>F</given-names></name><etal/></person-group><article-title>TGF-&#x003b2;&#x00026;nbsp;inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><issue>4</issue><fpage>1910</fpage><lpage>1922</lpage><pub-id pub-id-type="doi">10.7150/thno.36936</pub-id><?supplied-pmid 32042344?><pub-id pub-id-type="pmid">32042344</pub-id>
</element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy</article-title><source>Mol Ther</source><year>2019</year><volume>27</volume><issue>1</issue><fpage>244</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2018.11.010</pub-id><?supplied-pmid 30527756?><pub-id pub-id-type="pmid">30527756</pub-id>
</element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dammeijer</surname><given-names>F</given-names></name><name><surname>Lievense</surname><given-names>LA</given-names></name><name><surname>Kaijen-Lambers</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy</article-title><source>Cancer Immunol Res</source><year>2017</year><volume>5</volume><issue>7</issue><fpage>535</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-16-0309</pub-id><?supplied-pmid 28536100?><pub-id pub-id-type="pmid">28536100</pub-id>
</element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Eissler</surname><given-names>N</given-names></name><name><surname>Blanc</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma</article-title><source>Clin Cancer Res</source><year>2016</year><volume>22</volume><issue>15</issue><fpage>3849</fpage><lpage>3859</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-1912</pub-id><?supplied-pmid 26957560?><pub-id pub-id-type="pmid">26957560</pub-id>
</element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Vasudevaraja</surname><given-names>V</given-names></name><etal/></person-group><article-title>Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy</article-title><source>Elife</source><year>2020</year><volume>9</volume><fpage>e52253</fpage><pub-id pub-id-type="doi">10.7554/eLife.52253</pub-id><?supplied-pmid 32909947?><pub-id pub-id-type="pmid">32909947</pub-id>
</element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yagi</surname><given-names>T</given-names></name><name><surname>Baba</surname><given-names>Y</given-names></name><name><surname>Okadome</surname><given-names>K</given-names></name><etal/></person-group><article-title>Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer</article-title><source>Eur J Cancer</source><year>2019</year><volume>111</volume><fpage>38</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2019.01.018</pub-id><?supplied-pmid 30822683?><pub-id pub-id-type="pmid">30822683</pub-id>
</element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer</article-title><source>J Cancer</source><year>2022</year><volume>13</volume><issue>13</issue><fpage>3434</fpage><lpage>3443</lpage><pub-id pub-id-type="doi">10.7150/jca.77619</pub-id><?supplied-pmid 36313041?><pub-id pub-id-type="pmid">36313041</pub-id>
</element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Huang</surname><given-names>TW</given-names></name><name><surname>Hsieh</surname><given-names>YT</given-names></name><etal/></person-group><article-title>Cancer-Derived Succinate Promotes Macrophage Polarization and Cancer Metastasis via Succinate Receptor</article-title><source>Mol Cell</source><year>2020</year><volume>77</volume><issue>2</issue><fpage>213</fpage><lpage>227.e5</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.10.023</pub-id><?supplied-pmid 31735641?><pub-id pub-id-type="pmid">31735641</pub-id>
</element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Correction:&#x00026;nbsp;Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3K&#x003b3; to Promote Pancreatic Cancer Metastasis</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>4</issue><fpage>922</fpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-3872</pub-id><?supplied-pmid 32060228?><pub-id pub-id-type="pmid">32060228</pub-id>
</element-citation></ref></ref-list></back></article>